MARKET

MDNAF

MDNAF

Medicenna Therapeutics Corp
OTCQX
0.298
-0.016
-4.98%
Opening 09:38 06/09 EDT
OPEN
0.310
PREV CLOSE
0.314
HIGH
0.310
LOW
0.298
VOLUME
22.00K
TURNOVER
6.63K
52 WEEK HIGH
1.400
52 WEEK LOW
0.153
MARKET CAP
27.50M
P/E (TTM)
-2.6316
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MDNAF last week (0601-0605)?
Weekly Report · 1d ago
Medicenna highlights Phase 1b NEO-CYT trial testing MDNA11 combo in neoadjuvant melanoma at ASCO 2026
PUBT · 6d ago
Weekly Report: what happened at MDNAF last week (0525-0529)?
Weekly Report · 06/01 10:04
Medicenna closes marketed public unit offering raising CDN$4.44 million at CDN$0.5 per unit
PUBT · 05/28 13:11
MEDICENNA ANNOUNCES CLOSING OF PUBLIC OFFERING OF UNITS RAISING CDN$4.44 MILLION TO SUPPORT LEAD PROGRAMS
Reuters · 05/28 13:10
Weekly Report: what happened at MDNAF last week (0518-0522)?
Weekly Report · 05/25 10:07
Medicenna prices marketed unit offering at $0.5, targets up to $5 million
PUBT · 05/22 11:03
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
Barchart · 05/22 06:00
More
About MDNAF
Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.

Webull offers Medicenna Therapeutics Corp stock information, including OTCQX: MDNAF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDNAF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDNAF stock methods without spending real money on the virtual paper trading platform.